Arcturus Therapeutics (NASDAQ:ARCT) Raised to “Sell” at Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Arcturus Therapeutics Trading Down 4.9%

NASDAQ ARCT opened at $7.05 on Friday. The stock’s 50 day moving average is $6.76 and its 200 day moving average is $7.39. Arcturus Therapeutics has a 12 month low of $5.50 and a 12 month high of $24.17. The stock has a market cap of $200.36 million, a PE ratio of -2.13 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, analysts forecast that Arcturus Therapeutics will post -3.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARCT. BlackRock Inc. purchased a new stake in Arcturus Therapeutics during the second quarter valued at approximately $17,566,000. ARK Investment Management LLC raised its holdings in Arcturus Therapeutics by 39.4% during the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after buying an additional 738,378 shares during the period. Amova Asset Management Americas Inc. lifted its position in Arcturus Therapeutics by 12.9% in the first quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after buying an additional 262,347 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after buying an additional 262,347 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Arcturus Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after buying an additional 75,440 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.